Radar · Ophthalmology in United States
Best Ophthalmology Companies in United States
The 533 best Ophthalmology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kriya Therapeutics.
By Riya SenguptaFinancials
533companies tracked
$12.4Bdisclosed funding
1unicorns
300have raised
The 533 Ophthalmology companies tracked here are ranked by disclosed equity funding and recent momentum, giving you a clear-eyed read on where capital is actually flowing across the United States. Total disclosed funding hits $12.4B across this directory, with Kriya Therapeutics leading at $618M raised, Science close behind at $360M, and Beacon Therapeutics pulling $291M. One unicorn sits in the mix. Most active backers include HHS, Versant Ventures, and the NIH, which tells you something about how much of this sector's fuel still runs through public and institutional channels.
The revenue picture is more grounded. Median revenue across validated filers is $18M, with a -10% YoY growth rate that signals real pressure at the middle of the market. But the spread is stark. Glaukos Corp filed $151M in revenue, 8x the sector median, and growth foreseen for ophthalmology pegs the global market at roughly $20.7B in 2022, forecast to reach $23.2B by 2030 at a 6.4% CAGR. Synergetics USA pulled $75M, four times the median, with a healthy 16% YoY gain. And I'd note the combined revenue pool of these filers lands near $361M, which is real earned revenue, not funding rounds. Hot operational themes right now are vision care hospitals and ophthalmic surgery centers, a trend NYU Ophthalmology is leaning into with its first virtual eye hospital launch.
Ranked: Best Ophthalmology companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | 2012 | Shankar Ramaswamy Co-Founder & CEO | 5 signals Funding · Capital raise · Leadership | — | — |
| 2 | Science 🦄 Provider of online science magazine 72Funding top 13%Patents top 20%Moat top 24%Innovation top 33% All 9 signals ▾Fundingtop 13% Patentstop 20% Moattop 24% Innovationtop 33% Growthtop 35% Markettop 38% Globaltop 42% Talentbottom 49% Techbottom 46% Funding: Raised $360M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Patents: 245 patents matched (strict assignee match) · 102 filings since 2022 vs 115 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $360M | 3 mo ago | 76 | 2021 | Max Hodak Founder & CEO | — | 245 patents Specialty surfactants and polyether polymer derivatives for cosmetics and advanced chemical synthesis | 3 job openings · 1 award |
| 3 | Beacon Therapeutics Developer of therapeutics for retinal disorders | $291M | 5 mo ago | 76 | 2023 | Lance Baldo Chief Executive Officer | — | — | — |
| 4 | Tenvie Developer of small molecule therapies for neurological, cardiometabolic, and ophthalmic diseases | $200M | 17 mo ago | — | 2012 | Brian Cuneo Co-Founder & CLO | — | — | 4 job openings |
| 5 | Noveome Developer of biologically active molecules for the treatment of Periodontitis and inflammation diseases | $170M | 13 mo ago | 15 15 → 30 (+100%) | 2000 | — | — | — | — |
| 6 | ONL Therapeutics Developer of small peptide molecule to prevent the death of photoreceptor cells | $146M | 21 mo ago | 29 | 2011 | — | — | — | — |
| 7 | Ashvattha Therapeutics Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases 45Funding top 23%Moat top 36%Talent top 38%Market bottom 41% All 6 signals ▾Fundingtop 23% Moattop 36% Talenttop 38% Marketbottom 41% Globalbottom 37% Newsbottom 22% Funding: Raised $130M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $130M | 17 mo ago | 40 | 2015 | Kannan Rangaramanujam Co-Founder & CTO | — | — | — |
| 8 | Ray Therapeutics Developer of therapeutics for degenerative retinal diseases 48Funding top 19%Growth top 35%Tech top 40%Moat top 42% All 7 signals ▾Fundingtop 19% Growthtop 35% Techtop 40% Moattop 42% Talentbottom 49% Globalbottom 39% Marketbottom 28% Funding: Raised $106M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $106M | 1 mo ago | 10 | 2021 | Paul Bresge Co-Founder & CEO | — | — | — |
| 9 | Lineage Cell Therapeutics Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders | $94M | 25 mo ago | 75 | 1990 | Brian Culley CEO | 5 signals ▼64% Earnings | — | — |
| 10 | SpyGlass Developer of therapies for chronic ophthalmic disorders | $90M | 12 mo ago | 15 | 2020 | Patrick Mooney CEO | 7 signals ▲250% IPO · Earnings | — | — |
| 11 | Atsena Therapeutics Developer of gene therapies for the treatment of ocular diseases | $88M | 9 mo ago | 23 23 → 49 (+113%) | 2020 | Shannon Boye Founder & Director | — | — | 1 partnership |
| 12 | Eyconis Developer of ophthalmology therapeutics for diseases like AMD, DME, RVO, and GA | $85M | 8 mo ago | — | 2024 | Emmett Cunningham Co-Founder & Executive Chairman of the Board | — | — | 1 job opening |
| 13 | Trefoil Therapeutics Developer protein engineering drugs to treat corneal endothelial diseases | $73M | 13 mo ago | 10 | 2014 | Michael Blaber Co-Founder | — | — | — |
| 14 | Tenpoint Therapeutics Developer of engineered cell-based therapeutics to restore vision 50Funding top 23%Talent top 23%Moat top 31%Growth top 33% All 8 signals ▾Fundingtop 23% Talenttop 23% Moattop 31% Growthtop 33% Techtop 49% Newstop 49% Globalbottom 39% Marketbottom 26% Funding: Raised $70.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 8 named leaders on record · 8 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $70M | 4 mo ago | 14 | 2020 | Jose Sahel Co-Founder | 3 signals ▲50% Funding | — | — |
| 15 | Epicrispr Bio Developer of therapeutics for multiple disease 35Funding top 23%Talent top 38%Moat top 42%Tech bottom 43% All 6 signals ▾Fundingtop 23% Talenttop 38% Moattop 42% Techbottom 43% Globalbottom 37% Marketbottom 32% Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $68M | 14 mo ago | — | 2018 | Lei Qi Founder | — | — | — |
| 16 | Xequel Bio Developer of therapeutics for multiple indications | $63M | 16 mo ago | 16 | 2005 | Jerry Peter CEO | — | — | — |
| 17 | Claris Bio Developer of a topical formulation for the treatment of corneal wounds, ulcers, and scars | $57M | 9 mo ago | 4 | 2018 | Sunil Chauhan Co-Founder | — | — | — |
| 18 | Sydnexis Developer of a therapeutic formulation for treating myopia | $51M | 14 mo ago | — | 2014 | Jacqueline Johnson Co-Founder & COO | — | 119 patents Deuterated muscarinic antagonist ophthalmic formulations for pupil dilation and presbyopia treatment. | 1 launch |
| 19 | Kalaris Therapeutics Developer of therapeutics for retinal disorders | $50M | 6 mo ago | — | 2024 | Srinivas Akkaraju Co-Founder & Director | — | — | — |
| 20 | Qlaris Bio Provides AI-based technology for treating ophthalmic diseases 35Funding top 29%AI top 45%Tech top 48%Moat top 48% All 7 signals ▾Fundingtop 29% AItop 45% Techtop 48% Moattop 48% Talenttop 50% Globalbottom 36% Marketbottom 25% Funding: Raised $49.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 35/100 | $49M | 7 mo ago | 9 | 2019 | Thurein Htoo Chief Executive Officer & Co-Founder | — | — | — |
| 21 | Aviceda Therapeutics Developer of biotherapeutics for glycol-immune diseases | $47M | 18 mo ago | 16 | 2018 | Christopher Scott Co-Founder | — | — | — |
| 22 | Stellular Bio Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells 37Funding top 28%Talent top 28%Moat bottom 38%Global bottom 37% All 5 signals ▾Fundingtop 28% Talenttop 28% Moatbottom 38% Globalbottom 37% Marketbottom 32% Funding: Raised $44.5M across 9 rounds · 9 rounds over 10 yrs (0.9/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $44M | 4 mo ago | 12 | 2014 | Joseph Italiano Co-Founder | — | — | — |
| 23 | TearSolutions Topical therapeutics for the treatment of dry eye disease | $37M | 7 mo ago | 9 | 2013 | — | — | 38 patents Stabilized therapeutic peptides for ocular dry‑eye and pancreatic islet treatments | — |
| 24 | Viridian Therapeutics Developer of medicines for patients with serious and rare diseases | $34M | 1 mo ago | 94 | 2007 | — | 8 signals ▲167% Regulatory · Funding · Earnings | — | — |
| 25 | Nacuity Pharmaceuticals Developer of therapies for treating retinitis pigmentosa | $31M | 6 mo ago | 7 | 2016 | Halden Conner CEO & President | — | — | — |
| 26 | LumiThera Developer of photobiomodulation treatments for ocular diseases | $26M | 15 mo ago | 18 18 → 16 (-11%) | 2013 | James Carroll Co-Founder | — | 41 patents Non‑invasive multi‑wavelength phototherapy devices for ocular and tissue disease treatment. | — |
| 27 | Opus Genetics Developer of gene therapies to treat retinal degenerative diseases 42Patents top 29%Funding top 30%Moat top 32%Innovation top 34% All 11 signals ▾Patentstop 29% Fundingtop 30% Moattop 32% Innovationtop 34% Talenttop 38% Growthtop 47% Techtop 50% Newstop 50% Globalbottom 36% Marketbottom 31% Fin. healthbottom 28% Patents: 26 patents matched (strict assignee match) · 26 filings since 2022 vs 0 in 2017-21 Funding: Raised $23.5M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $24M | 10 mo ago | 14 | 2021 | Jason Menzo Co-Founder | 4 signals ▼20% Regulatory · Earnings · Funding | 26 patents Ophthalmic alpha‑adrenergic antagonist drugs for mydriasis, presbyopia, and AMD treatment | — |
| 28 | VisionQuest Biomedical Diagnostic devices for ophthalmic diseases and diabetic complications. | $23M | 14 mo ago | 9 | 2007 | — | — | — | — |
| 29 | Iantrek Developer of a minimally invasive eye surgery technology 60Growth top 15%News top 22%Innovation top 27%Patents top 27% All 9 signals ▾Growthtop 15% Newstop 22% Innovationtop 27% Patentstop 27% Fundingtop 29% Moattop 36% Talentbottom 49% Globalbottom 40% Marketbottom 21% Growth: Fresh capital in last 24 mo News: 6 BI events in 12 mo (of 10 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $23M | 1 mo ago | 2 | 2019 | Sean Ianchulev Founder & CEO | 6 signals ▲200% Funding · Capital raise | 62 patents Glaucoma treatment via biologic intraocular stents and aqueous drainage devices | 1 job opening · 1 launch |
| 30 | Vinci Pharmaceuticals Developer of a drug delivery technology for ophthalmic diseases | $20M | 5 mo ago | 3 | 2019 | Philip Gioia Chief Executive Officer | — | — | — |
| 31 | Kiora Pharmaceuticals Developer of therapies for the treatment of different types of eye diseases | $20M | 2 mo ago | 12 12 → 17 (+42%) | 2013 | Brian Strem CEO | — | — | 1 launch |
| 32 | Character Biosciences Developer of therapeutics for the treatment of age-related eye diseases | $18M | 9 mo ago | 30 | 2019 | Marcel Brug Co-Founder | 3 signals ▲200% Capital raise | — | — |
| 33 | Iolyx Therapeutics Developer of therapeutics for autoimmunity and ophthalmological conditions | $15M | 6 mo ago | — | 2019 | Elizabeth Jeffords CEO & President | — | — | — |
| 34 | Cirrus Therapeutics Developer of therapies designed to extend ocular healthspan and restore vision | $11M | 10 mo ago | — | 2021 | Andrew Dick Co-Founder | — | — | 1 award |
| 35 | Eyenovia Developer of microdose therapies for treating myopia | $10M | 11 mo ago | 41 | 2014 | — | — | 122 patents Micro‑dose ophthalmic fluid delivery devices for precise eye drug administration | — |
| 36 | Bioptics Technology Developer of fluorescence imaging devices and cerebral blood flow monitoring systems | $7M | 9 mo ago | — | 2019 | Cindy Sun Founder & CEO | — | — | — |
| 37 | GelMEDIX Developer of a hydrogel drug delivery technology for ophthalmic treatment | $6M | 3 mo ago | 9 | 2019 | Nasim Annabi Co-Founder | — | 26 patents Hydrogel biomaterials for cell encapsulation and tissue engineering applications. | — |
| 38 | Betaliq Developer of patented technology-based products for vision care | $6M | 12 mo ago | — | 2018 | Barry Butler CEO | — | — | — |
| 39 | Retivue Innovative retinal screening solutions for early eye disease detection and blindness prevention | $6M | 14 mo ago | 5 | 2011 | Paul Yates Founder & CEO | — | 26 patents Patents concentrated in health & consumer products | — |
| 40 | TECLens Developer of a noninvasive vision correction treatment | $6M | 16 mo ago | — | 2013 | David Acker Executive Chairman and Co-founder | — | 48 patents Patents concentrated in health & consumer products | 1 job opening · 1 launch |
| 41 | Avisi Technologies Developer of nano-materials 21News top 34%Talent top 41%Funding top 42%Moat top 47% All 8 signals ▾Newstop 34% Talenttop 41% Fundingtop 42% Moattop 47% Patentsbottom 42% Globalbottom 39% Innovationbottom 35% Marketbottom 30% News: 4 BI events in 12 mo (of 8 tracked, 1 types) · Top themes: Funding Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 21/100 | $5M | 3 mo ago | 15 | 2017 | Rui Jiang Co-Founder & CEO | 4 signals Funding | 4 patents Ophthalmic therapeutic devices for delivering/tuning eye disease treatments | 1 award |
| 42 | ZIPLYFT Provider of a minimally invasive surgery solution for blepharoplasty procedure | $5M | 5 mo ago | — | 2020 | Patricia Buehler Co-Founder & CEO | — | — | 1 partnership |
| 43 | Bio Usawa Developer of immunotherapy for cancer treatment | $3M | 7 mo ago | — | 2023 | Richard Chin Co-Founder | — | — | — |
| 44 | SightStream Developer of of corneal edema and regenerative therapies | $2M | 8 mo ago | 3 | 2022 | Jason Werner CEO | — | — | — |
| 45 | Mati Therapeutics Developing sustained drug delivery platform for ocular diseases, improving patient outcomes | $2M | 9 mo ago | — | 2012 | Bob Butchofsky Founder and CEO | — | 165 patents Ocular sustained‑release drug delivery systems and lacrimal duct implant technologies. | — |
| 46 | LaserSight Technologies Laser technologies for refractive vision correction | $1M | 3 mo ago | 20 | 1994 | — | — | — | — |
| 47 | OpZira Developer of technologies for early detection and monitoring of ocular diseases | $1M | 3 mo ago | — | 2025 | Clark Tedford CEO | — | — | — |
| 48 | BioLattice Developer of solutions for tissue repair and restoration | $849K | 3 mo ago | — | 2017 | Amelia Zellander Co-Founder & CEO | — | — | 1 internship · 1 award |
| 49 | LambdaVision Provider of a protein-based retinal prosthesis for retinal degenerative diseases | $650K | 7 mo ago | 7 | 2009 | — | — | 6 patents Retinal cell stimulation therapies for vision restoration | 1 partnership |
| 50 | Omega Ophthalmics Developer of intraocular lens for the treatment of a cataract | $450K | 5 mo ago | — | 2012 | Rick Ifland CEO | — | 166 patents Intraocular lens capsular bag prosthetic devices for cataract surgery | — |
Top 12 Ophthalmology companies in United States
#1
Science 🦄Series C · Alameda, California · founded 2021 · 76 employees$360Mraised▾
Science 🦄
Series C · Alameda, California · founded 2021 · 76 employees
Provider of online science magazine. They specialize in offering content in various topics such as science for patients,technologies and much more.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 13%Patents
top 20%Moat
top 24%Innovation
top 33%Growth
top 35%Market
top 38%Funding: Raised $360M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series C (Feb 2026)
Patents: 245 patents matched (strict assignee match) · 102 filings since 2022 vs 115 in 2017-21 · Latest publication 2026
Moat: IP moat: 245 patents · Unicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 14k LinkedIn followers — 8.2% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Senior Regulatory Specialist, Customer Service Engineer
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Feb 2026Series C$230M
- Mar 2025Series C$104M
- May 2024Series B$26M
Founders & team
Investors
Khosla Ventures, Lightspeed Venture Partners, Y Combinator, Quiet Capital, In-Q-Tel, Olive Capital
Tech stack
Apple Icloud MailAstroChakra UiDocusignEmotionGoogle Workspace
#2
Series B · Berkeley, California · founded 2021 · 10 employees$106Mraised▾
Series B · Berkeley, California · founded 2021 · 10 employees
Developer of therapeutics for degenerative retinal diseases. The lead candidate RAY-001 for Retinitis pigmentosa, RAY-002 for geography atrophy, and for other inherited retinal diseases.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 19%Growth
top 35%Tech
top 40%Moat
top 42%Talent
bottom 49%Global
bottom 39%Funding: Raised $106M across 6 rounds · 6 rounds over 4 yrs (1.5/yr) · Last round Series B (Apr 2026)
Growth: Fresh capital in last 24 mo
Tech: 36 technologies across 4/8 capability areas · Cloud: Cloudflare, Fastly · Devops: Nginx, Varnish
Audience (LinkedIn): 8k LinkedIn followers — 4.6% of this cohort's audience
Funding rounds
- Apr 2026Series B$125M
- Apr 2025Grant (prize money)$8M
- Nov 2023Grant (prize money)$4M
- May 2023Series A$100M
Founders & team
Investors
4Bio Capital, Novo Holdings, Deerfield, MRLV, Platanus, Norwest
Tech stack
CloudflareCloudflare Bot ManagementComplianzCore-JsElementorGenesis Blocks
#3
Series C · Alachua, Florida · founded 2023 · 76 employees$290.7Mraised▾
Series C · Alachua, Florida · founded 2023 · 76 employees
Developer of therapeutics for retinal disorders. It offers gene therapies which include AGTC-501, to treat X-linked retinitis pigmentosa (XLRP), and other pipeline candidates for dry age-related macular degeneration and cone-rod dystrophy.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 10k LinkedIn followers — 5.8% of this cohort's audience
Funding rounds
- Jan 2026Series C$75M
- Jul 2024Series B$170M
- Jun 2023Series A$120.7M
Founders & team
Investors
Oxford Science Enterprises, University of Oxford, Syncona, Forbion, TCG Crossover, Advent Life Sciences
Tech stack
AosCloudflareCloudflare Browser InsightsComplianzHstsHttp/3
#4
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#5
Public · Boulder, Colorado · founded 2007 · 94 employees$34.5Mraised▾
Public · Boulder, Colorado · founded 2007 · 94 employees
Developer of medicines for patients with serious and rare diseases. The company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 29k LinkedIn followers — 16.6% of this cohort's audience
Funding rounds
- May 2026Post IPO$20M
- Feb 2015Series A$8.5M
- Sep 2010Series A$6M
Investors
Fairmount Funds Management, MRLV, Longitude Capital, Broadview Ventures
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesDocusignFancybox
#6
Series C · White Plains, New York · founded 2019 · 2 employees$23Mraised▾
Series C · White Plains, New York · founded 2019 · 2 employees
Developer of a minimally invasive eye surgery technology. It offers an implantable biologic stent which is surgically implanted in tandem for increased aqueous outflow and lowering intraocular pressure.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Growth
top 15%News
top 22%Innovation
top 27%Patents
top 27%Funding
top 29%Moat
top 36%Growth: Fresh capital in last 24 mo
News: 6 BI events in 12 mo (of 10 tracked, 3 types) · +200% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Innovation: 62 patents (top 41% of patent-holders) · 49 filings since 2022 vs 13 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 6k LinkedIn followers — 3.6% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Regional Sales Director (Central) & Director of Strategic Operations
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Apr 2026Series C$30M
- Aug 2025Series C$42M
- Feb 2025Series B$2.8M
- Aug 2022Series B$23M
Founders & team
Investors
Visionary Ventures, Sectoral, USVP, JSD I Radius Special Situations, Civilization Ventures, aMoon
#7
Series B · Seattle, Washington · founded 2020 · 14 employees$70Mraised▾
Series B · Seattle, Washington · founded 2020 · 14 employees
Developer of engineered cell-based therapeutics to restore vision. The company is advancing cell-based therapies and in vivo reprogramming to restore vision loss caused by the deterioration of functional tissue for people with degenerative ocular diseases.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 23%Talent
top 23%Moat
top 31%Growth
top 33%Tech
top 49%News
top 49%Funding: Raised $70.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Talent: 8 named leaders on record · 8 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jan 2026Conventional Debt$150M
- Jan 2026Series B$85M
- Jul 2023Series A$70M
- 2021Seed—
Founders & team
Investors
British Patient Capital, F-Prime Capital, Sofinnova Partners, Qiming, Eight Roads Ventures, UCL Technology Fund
Tech stack
AccessibeAnime.JsCookieyesCore-JsElementorFastly
#8
Series A · Watertown, Massachusetts · founded 2014 · 12 employees$44.5Mraised▾
Series A · Watertown, Massachusetts · founded 2014 · 12 employees
Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells. It offers programmable logic controller platform focused on modifying the regenerative power of platelets, enabling researchers to create reengineering cell therapies.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 28%Talent
top 28%Moat
bottom 38%Global
bottom 37%Market
bottom 32%Funding: Raised $44.5M across 9 rounds · 9 rounds over 10 yrs (0.9/yr) · Last round Series A (Jan 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 1/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 883 LinkedIn followers
Funding rounds
- Jan 2026Series A—
- Mar 2025Grant (prize money)$356.5K
- Aug 2019Series A$26.4M
- May 2017Series A$10M
Founders & team
Investors
HHS, BioSciKin, National Heart Lung and Blood Institute, Vivo Capital, Nest Bio Ventures, Cockrell Interests
#9
Public · Salt Lake City, Utah · founded 2013 · 12 employees$20.2Mraised▾
Public · Salt Lake City, Utah · founded 2013 · 12 employees
Developer of therapies for the treatment of different types of eye diseases. The company lead product candidate KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and age-related retinal degeneration. Other drug candidates include KIO-101 for Dry Eye Disease, KIO-201 for PRK surgical recovery, and KIO-102 (Oral) for autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Apr 2026Post IPO$5M
- Jan 2024Post IPO$15M
- Feb 2023Post IPO$200K
Founders & team
Investors
Nantahala Capital Management, Rosalind Advisors, Stonepine, Velan Capital, ADAR1 Capital Management
Tech stack
AccessibeApache Http ServerBootstrapCloudflareCloudflare Bot ManagementCookieyes
#10
Series C · Durham, North Carolina · founded 2020 · 23 employees$88Mraised▾
Series C · Durham, North Carolina · founded 2020 · 23 employees
Developer of gene therapies for the treatment of ocular diseases. It leverages AAV.SPR, a novel spreading capsid, to evaluate best-in-class gene therapy candidate, ATSN-201, for X-linked retinoschisis a rare pediatric disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 14k LinkedIn followers — 7.9% of this cohort's audience
Activity: 1 partnerships (incl. patients and investigators) announced in 12 mo
Funding rounds
- Sep 2025Grant (prize money)$870.7K
- Mar 2025Series C$150M
- Oct 2023Series B$24.5M
- Dec 2020Series A$55M
Founders & team
Investors
Hatteras Venture Partners, Foundation Fighting Blindness, Sofinnova Investments, Abingworth, Lightstone Ventures, RD Fund
Tech stack
CloudflareCloudflare Bot ManagementCookieyesDocusignGodaddyGoogle Font Api
#11
Late Stage · Palo Alto, California · founded 2024$50Mraised▾
Late Stage · Palo Alto, California · founded 2024
Developer of therapeutics for retinal disorders. It offers a lead product, TH103 which is a fully humanized, recombinant fusion protein designed for intravitreal delivery as anti-VEGF agent for the treatment of neovascular age-related macular degeneration.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers — 3.4% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$50M
Founders & team
Investors
ADAR1, Coastlands Capital, RTW Investments, Samsara BioCapital, Woodline Partners, Invus
#12
Series C · Redwood City, California · founded 2024$85.3Mraised▾
Series C · Redwood City, California · founded 2024
Developer of ophthalmology therapeutics for diseases like AMD, DME, RVO, and GA. It focuses on creating long-acting and effective delivery methods for clinically validated and emerging medicines used in treating major causes of blindness. With TransCon technology for ophthalmology, it aims to develop transformational therapies for eye diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Hiring: 5 hiring posts in 12 mo (public) · momentum -3 · hiring: Senior Research Associate / Associate Scientist, Associate Scientist / Scientist
Funding rounds
- Oct 2025Series C$25M
- Jan 2024Series C$60.3M
Founders & team
Tech stack
Apple Icloud MailCloudflareGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
Funding & investor landscape
$12.4Btotal disclosed funding
311companies funded
1,174disclosed rounds
4rounds last 90 days
Most active investors
Notable founders
Max Hodak
Founder & CEO · Science
Paul Bresge
Co-Founder & CEO · Ray Therapeutics
Lance Baldo
Chief Executive Officer · Beacon Therapeutics
Shankar Ramaswamy
Co-Founder & CEO · Kriya Therapeutics
Roger Jeffs
Co-Founder · Kriya Therapeutics
Sean Ianchulev
Founder & CEO · Iantrek
Jose Sahel
Co-Founder · Tenpoint Therapeutics
Lyndon Cruz
Co-Founder · Tenpoint Therapeutics
Joseph Italiano
Co-Founder · Stellular Bio
Jonathan Thon
Founder · Stellular Bio
Brian Strem
CEO · Kiora Pharmaceuticals
Shannon Boye
Founder & Director · Atsena Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 11,129,114 docs
Market landscape — 10 sub-themes by coverage
Share of Ophthalmology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Medical Devices is moving in the United States
A read on the academic research around Medical Devices — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,830 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 43% → 57% across 2008–2026.
top research entities
- Johns Hopkins University74
- United States Food and Drug Administration59
- Harvard University54
- Center for Devices and Radiological Health53
- Design Intelligence36
leading researchers
www.rasitdinc.com · , Elena · Dmitry Oleynikov · Joseph S. Ross · Shane Farritor · Carl A. Nelson · Raşit Dinç · Barbara Christe
▲
Breakthroughs295 · 16%
▲ 15%→16% share
▲1.1× share momentum1 median citations53% since 2021mostly methods-led
Biocompatible material research is surging — U.S. papers rose from 2 to 9, driving Breakthroughs segment growth.
rising sub-themes (early→recent)
- Biocompatible material2→9
- Robotics7→13
- Health care1→6
- Tissue engineering1→5
- Automation1→5
Newly emergingWearable computer 0→7 · Gelatin 0→6 · Antimicrobial 0→6
Landmark Nanostructured Titanium for Biomedical Applications · 258 cites
◆
Advancements555 · 30%
31%→31% share
▲1.0× share momentum1 median citations53% since 2021mostly methods-led
Robotic surgery advancement papers intensified sharply, climbing from 18 to 29 across U.S. medical device research.
rising sub-themes (early→recent)
- Health care2→24
- MEDLINE1→21
- Quality (philosophy)3→15
- Robotic surgery18→29
- Product (mathematics)5→16
Newly emergingClearance 0→6 · Wearable computer 0→6 · Single use 0→6
Landmark New Technology and Health Care Costs — The Case of Robot-Assisted Surgery · 962 cites
▼
Concerns582 · 32%
▼ 35%→31% share
▼0.9× share momentum1 median citations51% since 2021mostly position pieces
MEDLINE-indexed concern papers exploded from 1 to 36, signaling rapidly escalating U.S. medical device safety scrutiny.
rising sub-themes (early→recent)
- MEDLINE1→36
- Robotic surgery7→24
- Patient safety19→32
- Key (lock)6→19
- Quality (philosophy)10→20
Newly emergingSystematic review 0→9 · Confidentiality 0→8 · Workflow 0→6
Landmark Current and emerging applications of 3D printing in medicine · 581 cites
RESEARCH HOTSPOTS · United States
Where medical devices is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston116 · +0.15
SF Bay Area70 · +0.06
New York59 · +0.21
Seattle40 · +0.25
Los Angeles36 · +0.38
Chicago33 · +0.16
Philadelphia28 · +0.12
San Diego27 · +0.36
Pittsburgh25 · +0.44
Atlanta23 · +0.43
PATENT SIGNAL · United States
Who's filing medical devices patents in the United States
United States medical devices patent filing is accelerating — 666,693 filings from 8,000 assignees (2016–2025), led by Covidien, Boston Scient Scimed, Medtronic; annual filings 63466→63610.
666,693 filings8,000 assigneespeak 71776/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Covidien29351
- Boston Scient Scimed24775
- Medtronic22434
- Becton Dickinson18269
- Procter & Gamble16210
- Ethicon ENDO Surgery13758
- Kimberly Clark12462
- Ethicon11769
Common questions
How many Ophthalmology companies are there in United States?
Radar tracks 533 indexable Ophthalmology companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Ophthalmology companies in United States?
The Ophthalmology companies in United States on this list have raised a combined $12.4B in disclosed equity funding across 311 funded companies.
Which is the highest-funded Ophthalmology company in United States?
Kriya Therapeutics is the highest-funded Ophthalmology company in United States, with $617.6M in disclosed equity funding.
How many Ophthalmology companies in United States are funded?
311 of the 533 Ophthalmology companies in United States on this list have disclosed at least one equity funding round.
How many Ophthalmology unicorns are there in United States?
1 Ophthalmology company in United States on this list is valued at $1B or more.
Who are the top investors in United States Ophthalmology companies?
The most active investors in United States Ophthalmology companies on this list include HHS, Versant Ventures, NIH, National Science Foundation, Visionary Ventures.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.